APSR2026-1044

Yes
Late-Breaking
Submitted
Poster Presentation
 
AP08-022
P77
 
Format: PPTX Only
https://storage.unitedwebnetwork.com/files/1285/1245311-46904-APSR-1044_439701.pdf
Format: PDF Only
06. Tuberculosis
9

No more than 15 authors can be listed.
Please ensure the authors are listed in the right order.
If there are multiple affiliations, please use the "+" button next to "Select Country/Region" to add additional affiliation fields.

Izumi Yamatani * The Research Institute of tuberculosis, Japan Anti-Tuberculosis Association Department of Mycobacterium Reference and Research Tokyo Japan Oita University Faculty of Medicine Respiratory Medicine and Infectious Diseases Oita Japan
Akio Aono - The Research Institute of tuberculosis, Japan Anti-Tuberculosis Association Department of Mycobacterium Reference and Research Tokyo Japan
Kinuyo Chikamatsu - The Research Institute of tuberculosis, Japan Anti-Tuberculosis Association Department of Mycobacterium Reference and Research Tokyo Japan
Shiomi Yoshida - The Research Institute of tuberculosis, Japan Anti-Tuberculosis Association Department of Mycobacterium Reference and Research Tokyo Japan
Yuriko Igarashi - The Research Institute of tuberculosis, Japan Anti-Tuberculosis Association Department of Mycobacterium Reference and Research Tokyo Japan
Yoshiko Shimomura - The Research Institute of tuberculosis, Japan Anti-Tuberculosis Association Department of Mycobacterium Reference and Research Tokyo Japan
Makiko Hosoya - The Research Institute of tuberculosis, Japan Anti-Tuberculosis Association Department of Mycobacterium Reference and Research Tokyo Japan
Yoshiro Murase - The Research Institute of tuberculosis, Japan Anti-Tuberculosis Association Department of Mycobacterium Reference and Research Tokyo Japan
Satoshi Mitarai - The Research Institute of tuberculosis, Japan Anti-Tuberculosis Association Department of Mycobacterium Reference and Research Tokyo Japan Nagasaki University Graduate School of Biomedical Sciences Department of Basic Mycobacteriosis Nagasaki Japan
 
 
 
 
 
 
Presenting Author Details
Izumi
Yamatani
yamataniizumi7@gmail.com
+819045143219
31-40
Japan
Original Research
Real-world evaluation of Deeplex Myc-TB for tuberculosis drug-resistance assessment in Japan
Maximum 25 words
Abstract Content
Targeted next-generation sequencing can provide rapid drug-resistance information for tuberculosis, but real-world data from low-incidence Asian settings remain limited. We evaluated Deeplex Myc-TB in a Japanese reference-laboratory setting.
We retrospectively reviewed cases tested by Deeplex Myc-TB between April 2025 and March 2026. Indications, specimen type, smear status, result availability, turnaround time, and resistance predictions were collected. Concordance with phenotypic drug susceptibility testing (pDST) was assessed using drug-specific denominators. Whole genome sequencing (WGS) data were available for 54. Deeplex TB XL was additionally evaluated in 24 cases.
Deeplex yielded results in 107 of 115 cases (93.0%): 75/78 culture isolates (96.2%) and 32/37 clinical specimens (86.5%). Failures comprised 3 isolates (2 non-positive MGIT cultures, 1 Ogawa culture) and 5 clinical specimens (smear-negative FFPE/lymph node, smear 1+ lymph node/BALF, and smear 2+ skin specimens). Results were obtained from smear-negative (n=2) and scanty/± specimens (n=4). Median turnaround time was 5 working days. The most common indications were detection of isoniazid and/or rifampicin resistance-associated mutations (25%), interpretation of pDST results (25%), and foreign birth or overseas stay (14%). Among 61 cases with pDST, 652 of 684 drug-case comparisons were concordant (95.3%). Concordance with pDST was low for ethambutol (44/51, 86.3%) and clofazimine (54/61, 88.5%). WGS-based review suggested that discordance was mainly attributable to mutations outside Deeplex target regions, uncertain or uncharacterised variants, low coverage, or pDST-related interpretive challenges. In an exploratory TB XL subset, additional or discrepant findings were observed in 12/24 cases, mainly involving extended or coverage-sensitive targets.
Deeplex Myc-TB was feasible in Japanese real-world cohort and provided clinically useful drug-resistance information within one working week. Discordance with pDST was limited and largely interpretable using WGS and coverage data. These findings support Deeplex Myc-TB as a rapid adjunctive tool for complex tuberculosis drug-resistance assessment in reference-laboratory practice.
 
 
 
 
 
No
No
 
JPG or JPEG or PNG format ONLY
Tuberculosis, Drug resistance, Targeted next-generation sequencing
maximum 3 keywords and no abbreviations, separated by commas
 
309